TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable or non-dilatable lesions, as it allows for calcium ablation or fracturing. 

TCT 2024 | Utilización de balones cubiertos de fármacos para el tratamiento de la rama lateral en técnica de stent provisional

The ECLIPSE study, a randomized trial, compared orbital atherectomy (OA) with balloon angioplasty (including cutting and scoring balloons) for the treatment of severely calcified lesions before drug-eluting stent (DES) implantation.

This study included patients with chronic and acute coronary syndromes (without ST elevation) and de novo lesions with severe calcification, as determined by angiography or intravascular ultrasound (IVUS)/optical coherence tomography (OCT), where plaque preparation was feasible with either therapy. 

A total of 2005 patients were enrolled across 104 US centers. Randomization was 1:1. The primary endpoints were (1) imaging analysis assessing minimal stent area (MSA) post-PCI, and (2) target vessel failure (TVF) at one year.

The average participant age was 69.9 years; 73.6% of subjects were men, and 23% had chronic kidney disease.

Read also: TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE.

In terms of the procedure, 47.6% of the orbital atherectomy group was treated via transfemoral access, 4.6% required a temporary pacemaker, 21.4% needed an extension catheter, and 42% used an OTW microcatheter or balloon. Intravascular imaging was used in 62.1% of procedures (40.3% of cases used OCT and 25.6%, IVUS).

In an analysis of the complications, there were low rates of no-reflow (0.3% vs 0.1%), type C-F dissections (6.9% vs 6.3%), and perforations (1.8% vs 1%, mostly Ellis type III). The incidence of slow flow was higher in the OA group (1.4% vs 0.4%; p=0.03). 

MSA in the most calcified region was 7.44 vs 7.05, a non-significant difference (-0.26 mm²; p=0.08). Regarding TVF at 1 year, orbital atherectomy showed an incidence of 11.5% vs 10.0% (hazard ratio [HR] 1.16; 95% confidence interval [CI] 0.87-1.54; p=0.28). 

Read also: TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting.

Regarding secondary endpoints, the OA group had higher cardiovascular mortality (p=0.005) and both groups had a similar stent thrombosis rate (0.7% vs 0.3%).

The authors concluded that routine use of orbital atherectomy did not improve MSA or reduce TVF compared with balloon PCI.

Presented by Ajay J Kirtane in the Late-Breaking Trials Sessions, TCT 2024, October 27-29, Washington, USA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

TCT 2024 | Distal Radial vs Transradial Approach in STEMI Patients

The transradial approach (TRA) has been recommended for patients with ST-elevation myocardial infarction (STEMI) for reduced bleeding complications and mortality. However, evidence in support...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...